Amgen Inc. v. Hospira, Inc.
1:15-cv-00839
Overview
Parties
Defendant
Hospira, Inc. Operating Company
Represented By
10 Attorneys ListedHeyman Enerio Gattuso & Hirzel LLP
300 Delaware Avenue, Suite 200, Wilmington, DE 19801
Plaintiff
Amgen Manufacturing, Limited NPE (University / Research)
Represented By
6 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Amgen Inc. Operating Company
Represented By
16 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Third Party Defendant
GlaxoSmithKline LLC NPE (University / Research)
Represented By
2 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 5,856,298 A Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 42,144,489 A | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 94,212,692 A | US Continuation / Sibling | View Official Patent → |
Amgen Inc. v. F. Hoffmann-LaRoche LTD
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5856298
Erythropoietin isoforms
|
Filed: 1994-11-03
Issued: 1999-01-05
|
Expired (Term Ended)
Expires: 2014-11-03
|
|
|
US5756349
Production of erythropoietin
|
Filed: 1995-06-06
Issued: 1998-05-26
|
Expired (Term Ended)
Expires: 2015-06-06
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
81
Dispositive
33
Granted
4
Denied
5
Pending / Review
71
Motions by Category
Key Dispositive Motions & Rulings